RETA - レアタ・ファ―マシュ―ティカルズ （Reata Pharmaceuticals Inc.） レアタ・ファ―マシュ―ティカルズRETAのチャート
RETAの企業情報
| symbol | RETA |
|---|---|
| 会社名 | Reata Pharmaceuticals Inc （レアタ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レアタ・ファーマスーティカルズ(Reata Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は製品候補の識別・開発・商品化に従事する。製品候補はミトコンドリア機能、酸化ストレス及び炎症生物学に関与する調節タンパク質の活性調節を含み、深刻で生命を脅かす疾患の患者の医療ニーズを満たす。同社の主力製品候補には結合組織疾患（CTD-PAH）に関連する肺動脈高血圧症（PAH）の第III相試験で研究されるバルドキソロンメチル、 フリードライヒ運動失調症、ミトコンドリア・ミオパチー症を含む複数の疾患の治療用フェーズⅡ臨床開発中の肺高血圧症（PH）、フリードライヒ運動失調症、ミトコンドリアミオパチー及び転移性黒色腫を含む疾患の治療用第II相臨床開発のOmaveloxoloneを含む。 レアタ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床ステ―ジで、酸化性ストレスと炎症に関連するタンパク質の活性を調整する薬剤を開発・商業化することに従事する。薬剤候補の「Bardoxoloneメチル」と「Omaveloxolone」は酸化防止剤炎症モジュレ―タからなる。本社はテキサス州ア―ビング。 Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency. |
| 本社所在地 | 2801 Gateway Drive Suite 150 Irving TX 75063 USA |
| 代表者氏名 | J. Warren Huff J.ウォーレンハフ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 972-865-2206 |
| 設立年月日 | 2002年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 93人 |
| url | www.reatapharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/reta |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -50.50300 |
| 終値（lastsale） | 66.97 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 1803.745 |
| 売上高 | 売上高（百万ドル） 62.48400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1743.66 |
| 当期純利益 | 当期純利益（百万ドル） -53.11500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Reata Pharmaceuticals Inc revenues increased 56% to $40M. Net loss increased 29% to $24.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 37% to $42.9M (expense) General and administrative - Balancing v increase of 56% to $14.2M (expense). |
RETAのテクニカル分析
RETAのニュース
Reata Pharmaceuticals Q2 2022 Earnings Preview 2022/08/05 18:05:36 Seeking Alpha
Reata Pharmaceuticals (RETA) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open.The consensus EPS Estimate is -$1.97 (-49.2% Y/Y) and the…
Reata Pharmaceuticals Earnings Preview 2022/08/05 16:19:17 Benzinga
Reata Pharmaceuticals (NASDAQ: RETA ) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here''s what investors need to know before the announcement. Analysts estimate that Reata Pharmaceuticals will report an earnings per share (EPS) of $-2.02. Reata Pharmaceuticals bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022 2022/08/01 10:45:00 Wallstreet:Online
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company’s business operations and clinical development programs on August 8, 2022, before the U.S. financial markets
Reata Pharmaceuticals Inc.: When The Timing Is Right, Sit Tight 2022/07/30 14:00:00 Stocks Register
Reata Pharmaceuticals Inc. (NASDAQ:RETA) price on Friday, July 29, rose 2.10% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $30.68. A look at the stock’s price movement, the close in the last trading session was $30.05, moving within a range at $29.72 and $30.98. The beta value … Reata Pharmaceuticals Inc.: When The Timing Is Right, Sit Tight Read More »
Reata Pharmaceuticals Inc. (NASDAQ: RETA) Stock: Can It Surge Further? 2022/06/20 15:00:00 Marketing Sentinel
In the last trading session, 0.87 million shares of the Reata Pharmaceuticals Inc. (NASDAQ:RETA) were traded, and its beta was 1.18. Most recently the company’s share price was $30.95, and it changed around $0.02 or 0.06% from the last close, which brings the market valuation of the company to $1.18B. RETA currently trades at a … Reata Pharmaceuticals Inc. (NASDAQ: RETA) Stock: Can It Surge Further? Read More »
Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%- Is Further Upside Left in the Stock? 2021/07/02 06:16:55 Nasdaq
Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock? Nasdaq
Movie theater industry has too many screens, former Regal CFO says 2021/06/09 01:36:34 Bitcoin Ethereum News
The post Movie theater industry has too many screens, former Regal CFO says appeared on BitcoinEthereumNews.com . AMC Entertainments revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree
AMC Has Too Many Screens: Insiders 2021/06/08 14:47:00 Baystreet Canada
AMC Entertainments (NYSE:AMC) revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree that moviegoing is not going to disappear. The pastime is inexpensive, enjoyable and can drive billions of dollars in ticket sales. In the last two weeks, the domestic box office has set ticket sales records for the pandemic era, a welcome sign of recovery for the industry. Its a particularly promising signal for AMC, which raised around $2 billion in cash over the last six months and plans to use some of the fresh funds to acquire more theater locations. Its best-case scenario is that the public will continue to turn out to see films on the big screen, and with more market share, AMC will reap the benefits of those ticket sales. As AMC moves to add more theaters, its searching for high-performing locations that were abandoned during the pandemic, it may also need to shed some of its underperforming cinemas.
Reata Pharmaceuticals Inc - Class A Shares Close the Week 23.2% Higher - Weekly Wrap 2021/05/28 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 23.2% higher than it did at the end of last week. The stock is currently up 10.6% year-to-date, down 5.9% over the past 12 months, and up 857.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.2%. Trading Activity Shares traded as high as $142.17 and as low as $113.37 this week.Shares closed 3e+1% below its 52-week high and 8e+1% above its 52-week low.Trading volume this week was 5.9% lower than the 10-day average and 14.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -60.8% The company's stock price performance over the past 12 months lags the peer average by -112.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Reata Pharmaceuticals Inc - Class A Shares Close the Week 41.6% Higher - Weekly Wrap 2021/05/21 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Reata Pharmaceuticals Inc - Class A Shares Close the Week 41.6% Higher - Weekly Wrap 2021/05/21 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.